ScholarLens Back to search
2020•NeurologyRequires access

Year 1 Performance of Adveva®, a Patient Support Program (PSP) for Patients Taking MAVENCLAD® (cladribine tablets) for Highly Active Relapsing Remitting Multiple Sclerosis (RRMS) in United Kingdom (UK) (1479)

Kate Morgan, Nadine Lott, Marco Lyons

Open publisher page 2 citations

Abstract

To present year 1 results of a patient-support program (PSP) for patients with highly active relapsing-remitting multiple sclerosis (RRMS) taking cladribine tablets (CT).

About this research paper

What this paper is about

To present year 1 results of a patient-support program (PSP) for patients with highly active relapsing-remitting multiple sclerosis (RRMS) taking cladribine tablets (CT).

Why it matters

OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

To present year 1 results of a patient-support program (PSP) for patients with highly active relapsing-remitting multiple sclerosis (RRMS) taking cladribine tablets (CT).

Key concepts: Cladribine, Relapsing remitting, Multiple sclerosis, Medicine, Family medicine, Internal medicine, Psychiatry

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
Year 1 Performance of Adveva®, a Patient Support Program (PSP) for Patients Taking MAVENCLAD® (cladribine tablets) for Highly Active Relapsing Remitting Multiple Sclerosis (RRMS) in United Kingdom (UK) (1479) — Research Paper | ScholarLens